On Monday, Sept. 28, the U.S. Food and Drug Administration approved a new treatment that targets dopamine pathways critical ...
Tavapadon (Juvmo) is the first selective D1/D5 dopamine receptor agonist approved for adult Parkinson disease, positioning a mechanistically differentiated oral, once-daily dopaminergic strategy.
When Pat Dunstan was diagnosed with Parkinson’s Disease, never in her wildest dreams did she imagine that her journey would lead to singing in a choir at Yankee Stadium before thousands of people. But ...
Dr. Fox Remains a Shareholder and Member of the Board of Directors; Board Members Dr. David McFarland & Dr. Lorraine ...
For individuals recovering from neurological conditions such as stroke, traumatic brain injury (TBI), multiple sclerosis, Parkinson's disease, vestibular dysfunction or concussion, outpatient ...
Parkinson's disease (PD) is a progressive neurological disorder that can significantly impact motor function and quality of life. In 2020 the total economic burden of PD in the United States was $51.9 ...
The SPEAK OUT!® Therapy Program, developed by Parkinson Voice Project, helps people with Parkinson’s and related disorders REGAIN and RETAIN their speech and swallowing. The program can improve volume ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results